Repatha (Evolocumab) and Cardiovascular Benefits in Diabetic Patients

Cardiovascular Benefits and LDL-C Reduction

• The 2023 American Diabetes Association guidelines acknowledge that PCSK9 inhibitors like evolocumab provide substantial LDL-C reduction and cardiovascular benefit when added to maximum tolerated statin therapy 1
• Evolocumab reduces LDL cholesterol by approximately 59% from baseline, achieving median LDL-C levels of 30 mg/dL in clinical trials 2

Clinical Application and Recommendations

• Evolocumab is FDA-approved as an adjunct to diet and maximally tolerated statin therapy for adults with established atherosclerotic cardiovascular disease or familial hypercholesterolemia who require additional LDL-C lowering 3
• The American College of Cardiology recommends evolocumab for high-risk patients unable to achieve >50% LDL cholesterol reduction on statin therapy 4

Important Considerations for Prescribing Evolocumab

• For patients with diabetes who have elevated cardiovascular risk, the European Society of Cardiology recommends lowering LDL-C to <1.4 mmol/L (<55 mg/dL) and reducing it by at least 50% from baseline 6